.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Julphar
Healthtrust
AstraZeneca
Argus Health
Baxter
Johnson and Johnson
Medtronic
Citi
Federal Trade Commission

Generated: November 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,536,516

« Back to Dashboard

Claims for Patent: 4,536,516

Title: Alkene derivatives
Abstract:Triphenylalkene derivatives, in particular 1-(p-.beta.-dimethylaminoethyoxyphenyl)-1,2-diphenylbut-1-ene, which possess utility as anti-oestrogens.
Inventor(s): Harper; Michael J. K. (Ferney-Voltaire, FR), Richardson; Dora N. (Macclesfield, GB2), Walpole, deceased; Arthur L. (Macclesfield, GB2)
Assignee: Imperial Chemical Industries PLC (London, GB2)
Application Number:06/600,224
Patent Claims: 1. The geometric isomer of 1-(p-.beta.-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1ene, and the pharmaceutically acceptable, acid addition salts thereof, which is identified by its citrate having a melting point of 140.degree.-142.degree. C.

2. 1-(p-.beta.-dimethylaminoethoxyphenyl)-trans-1,2-diphenylbut-1-ene and the pharmaceutically acceptable, acid addition salts thereof.

3. 1-(p-.beta.-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene citrate of melting point 140.degree.-142.degree. C.

4. In a process for the treatment of hormone dependent tumors, the improvement which comprises treating said tumors with an effective amount of a member of the group consisting of the geometric isomer of 1-(p-.beta.-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene, and the pharmaceutically acceptable, acid addition salts thereof, which isomer is identified by its citrate having a melting point of 140.degree.-142.degree. C.

5. In a process for the treatment of hormone dependent tumors, the improvement which comprises treating said tumors with an effective amount of a member selected from the group consisting of 1-(p-.beta.-dimethylaminoethoxyphenyl)-trans-1,2-diphenylbut-1-ene and the pharmaceutically acceptable, acid addition salts thereof.

6. In a process for the treatment of hormone dependent tumors, the improvement which comprises treating said tumors with an effective amount of 1-(p-.beta.-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene citrate of melting point 140.degree.-142.degree. C.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
UBS
Fuji
Moodys
Federal Trade Commission
Medtronic
Covington
Argus Health
Express Scripts
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot